ractigen

Ractigen’s RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant…

ractigenApril 9, 2025

Company News Homepage News Presentations

RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (Abstract)

Event: American Academy of Neurology (AAN) 2025 Annual Meeting (San Diego) View Abstract View News:…

ractigenApril 9, 2025

Company News Homepage News News Highlight RAG-01

Ractigen’s RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025

NANTONG, China, and MELBOURNE, Australia, March 24, 2025 – Ractigen Therapeutics, a clinical-stage biopharmaceutical company…

ractigenMarch 24, 2025

Presentations RAG-01 Presentation

First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(Abstract)

Event：40th Annual Congress of the European Association of Urology (EAU 2025) (Spain) View Abstract View…

ractigenMarch 24, 2025

Company News Homepage News News Highlight

Ractigen Therapeutics Founder Dr. Long-Cheng Li Awarded 2024 Life Science Ice Breaking Award

NANTONG and SUZHOU, China, Dec. 30, 2024 — Ractigen Therapeutics proudly announces that its Founder…

ractigenDecember 31, 2024

Company News

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

NANTONG and SUZHOU, China, Dec. 24, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated…

ractigenDecember 24, 2024

Company News

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated…

ractigenNovember 19, 2024

Presentations RAG-01 Presentation

Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment. (Abstract)

Event: 2024 Oligonucleotide Therapeutics Society Meeting (Montreal) View Abstract

ractigenOctober 11, 2024

Presentations

RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (Abstract)

Event: Society for Neuroscience Annual Meeting 2024 (Neuroscience 2024) (San Diego) View Abstract

ractigenOctober 7, 2024

Company News RAG-17

Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial

NANTONG and SUZHOU, China, Sep.10, 2024 — Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to…

ractigenSeptember 10, 2024